Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Chest Wall Disease
Interventions: BIOLOGICAL: Pembrolizumab|DRUG: Carboplatin|BIOLOGICAL: Trastuzumab
Sponsor: Hope Rugo, MD
Collaborators: Mayo Clinic|Johns Hopkins University|Translational Breast Cancer Research Consortium|Massachusetts General Hospital|Merck Sharp & Dohme LLC